A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 1
- Study design
- NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 18
- Population
- ALL · 50 Years
- Duration
- 2019-07-26 to 2022-08-09
- Intervention
- BI 754132
- Comparator
- Not reported
- Outcomes measured
- SRD Part: Number of Patients With Ocular (in the Study Eye) or Systemic Dose Limiting Events (DLEs) — From drug adminis…; MD Part: Number of Patients With Drug Related Adverse Events (AEs) — From drug administration until end of trial, up to…; SRD Part: Number of Patients With Drug-related Adverse Events (AEs) — From drug administration until end of trial, up t…; SRD Part: Number of Patients With Any Ocular Adverse Events (AEs) in the Study Eye — From drug administration until end…; SRD Part: Maximum Serum Concentration of BI 754132 After a Single Intravitreal Dose (Cmax) — At Day 1, 4, 8, 15, 29, 56…; SRD Part: Area Under the Concentration-time Curve of BI 754132 in Serum Over the Time Interval From 0 Extrapolated to I…; SRD Part: Time From Dosing to Maximum Serum Concentration of BI 754132 (Tmax) — At Day 1, 4, 8, 15, 29, 56, 84 and Day…; MD Part: Trough Levels of BI 754132 Before Second Administration (Cmin,1) — Up to 29 days.; MD Part: Trough Levels of BI 754132 Before Third Administration (Cmin,2) — Up to 57 days.; MD Part: Plasma Concentration of BI 754132 4, 8 and 14 Weeks After the Third Administration — At Day 85, 113 and Day 15…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.